Showing results (1-10 of 44) with videos related to
Sort By:
Pageof 5
Infectious Diseases and Therapy|February 25, 2015
Tedizolid Phosphate: a Next-Generation OxazolidinoneJeffrey M Rybak, Karrine RobertsPharmacotherapy|October 1, 2014
Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistanceJeffrey M Rybak, Kayleigh Marx, Craig A MartinExpert Opinion on Pharmacotherapy|July 24, 2013
Current and prospective treatments for multidrug-resistant gram-positive infectionsJeffrey M Rybak, Katie E Barber, Michael J RybakPharmacotherapy|August 21, 2015
The β-Lactams Strike Back: Ceftazidime-AvibactamEvan J Zasowski, Jeffrey M Rybak, Michael J RybakThe Journal of Antimicrobial Chemotherapy|December 19, 2018
Emerging threat of triazole-resistant Aspergillus fumigatusJeffrey M Rybak, Jarrod R Fortwendel, P David RogersCurrent Opinion in Microbiology|October 15, 2022
The molecular and genetic basis of antifungal resistance in the emerging fungal pathogen Candida aurisJeffrey M Rybak, Christina A Cuomo, P David RogersInfectious Diseases and Therapy|February 3, 2016
Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive InfectionsKarrine D Brade, Jeffrey M Rybak, Michael J RybakPharmacotherapy|February 16, 2020
Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative InfectionsJordan R Smith, Jeffrey M Rybak, Kimberly C ClaeysThe Journal of Infectious Diseases|June 26, 2025
A Candidozyma (Candida) auris-Optimized Episomal Plasmid-Induced Cas9-Editing System Reveals the Direct Impact of the S639F-Encoding FKS1 MutationLaura A Doorley, Vanessa Meza-Perez, Sarah J Jones, et al.Biorxiv : the Preprint Server for Biology|February 24, 2025
A <i>Candidozyma</i> ( <i>Candida</i> ) <i>auris</i> -optimized Episomal Plasmid Induced Cas9-editing system reveals the direct impact of the S639F encoding <i>FKS1</i> mutationLaura A Doorley, Vanessa Meza-Perez, Sarah J Jones, et al.Pageof 5